CELC shares fall premarket after rising late Tuesday when the FDA approved its drug for an advanced form of breast cancer, making it the com
CELC shares fall premarket after rising late Tuesday when the FDA approved its drug for an advanced form of breast cancer, making it the company's first product to gain market entry… but the company delayed the launch until late Q326 (more)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.